SCHEMBL4012307

SCHEMBL4012307

O=C(NCc1ccc(F)cc1)c1ccc(S(=O)(=O)n2nc(-c3ccccc3)c3ccccc32)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.53
CA2 P00918 2/20 0.50
CA1 P00915 1/20 0.50
PTGER4 P35408 2/20 0.49
ALDH1A1 P00352 2/20 0.48
RORC P51449 2/20 0.47
LMNA P02545 1/20 0.46
EPHX2 P34913 1/20 0.45
NR1H4 Q96RI1 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
DGAT2 Q96PD7 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4007300 0.86 CXCR4 (0.53) CXCR4CA2CA1PTGER4ALDH1A1
SCHEMBL4006291 0.86 CXCR4 (0.53) CXCR4CA2CA1PTGER4ALDH1A1
SCHEMBL4013046 0.81 ALDH1A1 (0.53) CXCR4PTGER4ALDH1A1LMNA
SCHEMBL4013129 0.81 ALDH1A1 (0.48) CXCR4PTGER4ALDH1A1RORCLMNA
SCHEMBL1413828 0.80 HTR6 (0.58) CXCR4CA2CA1PTGER4ALDH1A1
SCHEMBL4013097 0.80 TP53 (0.55) CXCR4ALDH1A1LMNAHDAC1
SCHEMBL4002900 0.78 CCR1 (0.49) CXCR4PTGER4ALDH1A1RORCLMNA
SCHEMBL13689663 0.78 CXCR4 (0.44) CXCR4PTGER4ALDH1A1RORC
SCHEMBL1413651 0.77 CXCR4 (0.54) CXCR4CA2CA1ALDH1A1RORC
SCHEMBL1413324 0.77 CXCR4 (0.54) CXCR4CA2CA1PTGER4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595339-B2 CB1 modulator compounds ELI LILLY AND COMPANY (US) 2009-09-29 US disclosed
US-7595339-B2 CB1 modulator compounds ELI LILLY AND COMPANY (US) 2009-09-29 US disclosed
US-20080287504-A1 CB1 MODULATOR COMPOUNDS ALLEN JENNIFER REBECCA 2008-11-20 US disclosed
US-20080287504-A1 CB1 MODULATOR COMPOUNDS ALLEN JENNIFER REBECCA 2008-11-20 US disclosed
US-7276516-B2 CB1 antagonist compounds ELI LILLY AND COMPANY (US) 2007-10-02 US disclosed
US-7276516-B2 CB1 antagonist compounds ELI LILLY AND COMPANY (US) 2007-10-02 US disclosed
US-7276516-B2 CB1 antagonist compounds ELI LILLY AND COMPANY (US) 2007-10-02 US disclosed
US-20070088018-A1 Cb1 antagonist compounds ELI LILLY AND COMPANY (US) 2007-04-19 US disclosed
US-20070088018-A1 Cb1 antagonist compounds ELI LILLY AND COMPANY (US) 2007-04-19 US disclosed
US-20070088018-A1 Cb1 antagonist compounds ELI LILLY AND COMPANY (US) 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088018-A1 Cb1 antagonist compounds CNR1, CNR2, CHRNA5 CXCR4 690/4885CA2 3947/4885CA1 1372/4885
US-20080287504-A1 CB1 MODULATOR COMPOUNDS CNR1, CNR2, MAG CXCR4 768/4885CA2 4091/4885CA1 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.